P
16.29
0.08 (0.49%)
| Previous Close | 16.21 |
| Volume | 1,690,052 |
| Price / Sales | 23.00 |
| Price / Book | 7.45 |
| 52 Weeks Range |
| Profit Margin | -98.10% |
| Operating Margin (TTM) | -85.88% |
| Diluted EPS (TTM) | -1.29 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Total Debt/Equity (MRQ) | 21.81% |
| Current Ratio (MRQ) | 6.91 |
| Operating Cash Flow (TTM) | -42.70 M |
| Levered Free Cash Flow (TTM) | -23.09 M |
| Return on Assets (TTM) | -17.90% |
| Return on Equity (TTM) | -51.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Personalis, Inc. | Mixed | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | -0.33 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 31.49% |
| % Held by Institutions | 46.11% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |